Prolactin (PRL) promotes cell proliferation, and PRL receptor expression is elevated in various cancer types.
However, only a few studies have examined cancer risk in patients with hyperprolactinemia (HPL).
The aim of this study was to investigate cancer risk in a nation-wide cohort of patients with a diagnosis of HPL, with special emphasis on breast cancer.
